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 Overexpression of the urokinase receptor splice 
variant uPAR-del4/5 in breast cancer cells affects 
cell adhesion and invasion in a dose-dependent 
manner and modulates transcription 
of tumor-associated genes 
 Abstract:  mRNA levels of the urokinase receptor splice 
variant uPAR-del4/5 are associated with prognosis in 
breast cancer. Its overexpression in cancer cells affects 
tumor biologically relevant processes. In the present 
study, individual breast cancer cell clones displaying low 
vs. high uPAR-del4/5 expression were analyzed demon-
strating that uPAR-del4/5 leads to reduced cell adhesion 
and invasion in a dose-dependent manner. Additionally, 
matrix metalloproteinase-9 (MMP-9) was found to be 
strongly upregulated in uPAR-del4/5 overexpressing com-
pared to vector control cells. uPAR-del4/5 may thus play 
an important role in the regulation of the extracellular 
proteolytic network and, by this, influence the metastatic 
potential of breast cancer cells. 
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 The urokinase-type plasminogen system mainly consists 
of the serine protease uPA, its serpin-type inhibitor PAI-1, 
and its cell surface receptor uPAR (CD87) and is intimately 
involved in several (patho-)physiological processes such as 
thrombolysis, inflammation, fertility, cell migration, tissue 
re-modeling, cancer cell invasion and metastasis, and vascu-
larization (Montuori et al. , 2005 ; Mengele et al. , 2010 ). Fur-
thermore, these factors represent important biomarkers in 
a number of malignancies, including breast cancer ( H ø yer-
Hansen and Lund, 2007 ; Schmitt et al. , 2010 ). uPAR, which 
is linked to the cell membrane  via its glycosyl phosphatidyl 
inositol (GPI) moiety, is an ubiquitously expressed 45 – 60 
kDa highly glycosylated protein. The receptor is composed 
of three homologous domains designated DI, DII, and DIII, 
from the amino- to the carboxy-terminus (Kriegbaum et al. , 
2011 ; Xu et al. , 2012 ). Upon binding of its ligand uPA, uPAR 
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focuses the extracellular proteolytic network, including 
plasmin and matrix metalloproteinases (MMPs), on the cell 
surface. In addition to its proteolysis-related functions, uPAR 
can act as a signaling receptor that modulates cell adhesion, 
migration, and proliferation through interactions with other 
membrane proteins such as several integrins, epidermal 
growth factor receptor (EGFR), G protein-coupled receptors, 
low-density lipoprotein receptor-related protein, and the 
extracellular matrix protein vitronectin (Tang and Wei , 2008 ; 
Blasi and Sidenius , 2010 ; Smith and Marshall , 2010 ). 
 Several mRNA splice variants of uPAR have been iden-
tified and their expression analyzed in human cells and 
tissues. One of these splice variants, uPAR-del4/5 (lacking 
exons 4 and 5), encodes a form of uPAR lacking the domain 
DII and was found to be overexpressed in breast cancer cells 
(Luther et al. , 2003 ). Interestingly, high uPAR-del4/5 mRNA 
expression levels were found to be significantly associated 
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lA Figure 1   Characterization of uPAR-del4/5 overexpressing CAMA-1 
cell clones. 
 CAMA-1 breast cancer cells were stably transfected with an expres-
sion plasmid encoding uPAR-del4/5 (pRcRSV-uPAR-del4/5) or the 
vector only (pRcRSV; Invitrogen, Karlsruhe, Germany), and individual 
cell clones isolated by limited dilution. (A) Western blot analysis. 
Cell pellets were lysed in TBS-T (Tris-bufferd saline, 1 % Triton X-100) 
containing the protease inhibitor cocktail  ‘ Complete with EDTA ’ 
(Roche Diagnostics, Mannheim, Germany). The cleared lysate was 
applied to a polyacrylamide gel. After electrophoresis, proteins were 
transferred to a PVDF membrane (Millipore Corporation, Bedford, 
MA) using a semidry blotting device. Domain I of uPAR was detected 
using the monoclonal antibody IIIF10 (Luther et al. , 1997 ), diluted 
in TBS-T supplemented with 1 % (w/v) dried skimmed milk. After 
several washes in TBS-T, binding of the antibodies was visualized by 
incubation of the membranes with a horseradish peroxidase-conju-
gated secondary goat antibody against mouse Ig (Jackson Immu-
noResearch Lab, West Grove, PA) followed by chemoluminescence 
reaction using ECL (Thermo Scientific, Pierce, Stonehouse, UK). (B) 
Adhesion of CAMA-1 breast cancer cells to collagen type IV. CAMA-1 
breast cancer cells were resuspended in culture medium containing 
0.5 % (w/v) BSA  + HEPES (Invitrogen), seeded at a density of 20 000 
cells/well on Col IV-coated 96-well plates (5  μ g/ml; Sigma-Aldrich, 
Saint Louis, MO), and allowed to adhere for 2 h at 37 ° C. Non-
adherent cells were subsequently removed by washing three times 
with phosphate-buffered saline (PBS). The number of adherent cells 
was quantified by a hexo saminidase activity assay. For this, cells 
were incubated with  p -nitrophenyl-N-acetyl- α -D-glucosaminide 
(Sigma-Aldrich) diluted to 15 mm in a 100-mm sodium citrate buffer, 
pH 5.0, 0.5 % (v/v) Triton X-100, for 90 min at 37 ° C. The reaction was 
terminated by the addition of stop buffer (0.2 m NaOH, 5 mm EDTA) 
and the optical density recorded at 405 nm. At least three independ-
ent experiments were performed in triplicates each. The results 
are given in  % relative to the cell number of adherent vector-trans-
fected control cells. Whisker box plots indicate the 25th and 75th 
percentile, the vertical bars indicate the 10th and 90th percentile. 
The median value is indicated by a bar within the box. Statistically 
significant differences ( p  <  0.05) are indicated by an asterisk. 
with shorter disease-free survival of breast cancer patients 
(Luther et al. , 2003 ; Kotzsch et al. , 2005 ). Moreover, uPAR-
del4/5 mRNA was shown to be a highly sensitive, statisti-
cally independent prognostic factor for distant metasta-
sis-free survival in untreated node-negative breast cancer 
patients (Kotzsch et al. , 2008 ). Recently, we described the 
characteristics of breast cancer cell lines overexpressing 
the urokinase receptor splice variant (Sato et al., 2011). 
Batch-transfected, uPAR-del4/5 overexpressing breast 
cancer cells showed a reduced adhesion toward the extra-
cellular matrix proteins as well as a decreased invasive 
capacity in Matrigel TM invasion assays  in vitro . Accordingly, 
the ability of batch-transfected cells to form lung colonies 
upon tail vein injection in an  in vivo athymic mouse model 
was significantly reduced (Sato et al., 2011). In the present 
study, individual cell clones of two different breast cancer 
cell lines expressing homogeneous high, medium, or low 
levels of uPAR-del4/5 were isolated and analyzed whether 
tumor biologically relevant characteristics of tumor cells 
are affected in a dose-dependent manner. Furthermore, 
we investigated whether overexpression of uPAR-del4/5 
in breast cancer cells modulates gene expression of other 
tumor-relevant factors. 
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 31.10.13 15:06
 B. Grismayer et al.: uPAR-del4/5 overexpression in breast cancer   1451
 First, individual cell clones were isolated by limited 
dilution from the breast cancer cell line CAMA-1, which 
has been stably transfected with an expression plasmid 
encoding uPAR-del4/5 or the vector alone as described 
previously (Sato et al., 2011). In Western blot analysis, the 
vector control cells do not display any uPAR-related signal, 
whereas the uPAR-del4/5 batch-transfected cells display 
moderate expression levels (Figure  1 A). Additionally, cell 
clones expressing uPAR-del4/5 protein at low, medium, or 
high uPAR-del4/5 levels could be generated (Figure 1A). 
Densitometric analysis of the Western blot indicated a 
relative uPAR-del4/5 expression level of 1 (low):3.7 (mod-
erate):6.1 (high). Cell growth of batch-transfected cells 
as well as individual cell clones, analyzed by cell count-
ing, was not affected by uPAR-del4/5 overexpression. 
However, the adhesive capacity of CAMA-1 cells toward 
different extracellular matrix (ECM) proteins distinctly 
changed. As seen in Figure 1B, uPAR-del4/5 high- and 
moderate-expressing CAMA-1 cell clones display a very 
low binding capacity toward collagen type IV (Col IV). 
The low-expressing cell clone, on one hand, is character-
ized by an about 40 % significantly lower binding capacity 
compared to the vector control cells. On the other hand, 
this clone binds about fourfold better to collagen type IV 
compared to the uPAR-del4/5 high-/moderate-expressing 
clones. Similar results were obtained when cell culture 
plates were precoated with collagen type I (Col I) or, to a 
lesser extent, vitronectin (VN) (data not shown). These 
results clearly demo nstrate that uPAR-del4/5 controls cell 
adhesion in CAMA-1 cells in a dose-dependent manner. 
 These findings were confirmed in a second breast 
cancer cell line, MDA-MB-231. These cells endogenously 
express low levels of wild-type uPAR, whereas uPAR-
del4/5 expression is not detectable even on the mRNA level 
by quantitative PCR. Again, individual cell clones were 
isolated by limited dilution, and low- and high-expressing 
clones were selected by flow cytofluorometry, applying 
monoclonal antibody IIIF10 directed against domain I of 
uPAR (Luther et al. , 1997 ) detecting both wild-type uPAR 
and uPAR-del4/5. These analyses indicated a relative 
cell surface-associated uPAR-reactive protein of 1 (vector 
control, endogenously expressing wild-type uPAR):1.5 
(low uPAR-del4/5-expressing clone):16 (high uPAR-del4/5-
expressing clone). Alike CAMA-1 cells, we did not observe 
any changes in cell proliferation upon stable transfection 
of the uPAR-del4/5 expression vector, neither in low- nor 
in high-expressing cell clones. In contrast, adhesion to 
the ECM proteins Col IV, Col I, and VN is significantly 
reduced by about 30 % in the high-expressing clone 
(Figures  2 A and  3 ). These results clearly validate previous 
results obtained with batch-transfected MDA-MB-231 cells 
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 Figure 2   Characterization of uPAR-del4/5-overexpressing MDA-MB-
231 cell clones. 
 (A) Adhesion of MDA-MB231 breast cancer cells to vitronectin. 
Ninety-six-well plates were coated with VN (2  μ g/ml; BD Bio-
sciences, Franklin Lakes, NJ) and cell adhesion quantified as 
described in Figure 1B. (B) Characterization of the invasive capacity 
of uPAR-del4/5-overexpressing MDA-MB-231 cell clones. Transwell 
inserts (8  μ m pore size; Corning Costar, Amsterdam, The Nether-
lands) were coated with 30  μ g basement membrane complex growth 
factor-reduced Matrigel TM (BD Biosciences). After incubation for 
3 h at 37 ° C followed by overnight incubation in a laminar hood at 
room temperature, inserts were rehydrated with 200  μ l FCS-free 
DMEM, containing 0.1 % (w/v) BSA, 2 h at 37 ° C. MDA-MB-231 cells 
were resuspended in culture medium and seeded in the upper 
chamber of the device at a density of 40 000 cells/chamber. The 
lower chambers were filled with 600  μ l DMEM supplemented with 
10 % (v/v) FCS as a chemoattractant. After a 24-h incubation at 37 ° C, 
Matrigel TM and non-invaded cells, located on the upper side of the 
insert, were wiped off, whereas invaded cells on the lower side of 
the insert were fixed, stained, and counted. At least three independ-
ent experiments were performed in triplicates each. The results are 
given in  % relative to the cell number of adherent vector-transfected 
control cells (A) or normalized to the number of invaded vector-
transfected cells (B). Whisker box plots indicate the 25th and 75th 
percentile, the vertical bars indicate the 10 th and 90 th percentile. 
The median value is indicated by a bar within the box. Statistically 
significant differences ( p  <  0.05) are indicated by an asterisk. 
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(Sato et al., 2011). Interestingly, already low expression 
of uPAR-del4/5 protein in MDA-MB-231 cells significantly 
affects the binding of the cells to VN (Figure 2A) and Col 
IV (data not shown). 
 To verify that the observed effects on cell adhe-
sion were specific to uPAR-del4/5 expression, and not 
merely due to cellular alterations resulting from protein 
overexpression, we also analyzed the overexpression of 
uPAR-wt in MDA-MB-231 cells. Wild-type uPAR has been 
shown to be involved in the regulation of cell adhesion, 
e.g., through interactions with integrins (Tang and Wei , 
2008 ). In fact, in contrast to uPAR-del4/5, overexpres-
sion of uPAR-wt protein led to an about twofold increased 
adhesion of MDA-MB-231 cells to the various ECM proteins 
(Figure 3). These results strongly suggest that upon over-
expression, uPAR-del4/5 and uPAR-wt, respectively, exert 
different effects on cell adhesion in breast cancer cells. In 
addition, our data indicate that the decrease of adhesion 
in uPAR-del4/5-overexpressing cells correlates with the 
respective uPAR-del4/5 protein levels. 
 Furthermore, the invasive capacity of the cell clones 
overexpressing uPAR-del4/5 was determined using 
Matrigel TM Transwell assays. For this, only the highly 
metastatic cell line MDA-MB-231 was used because paren-
tal CAMA-1 cells do not display any invasion through 
Matrigel TM . Batch-transfected uPAR-del4/5 expressing 
MDA-MB-231 cells showed a significant reduction in their 
invasive capacity, which corresponds to previous findings 
A
dh
er
en
t c
el
ls 
[%
 of
  v
ec
tor
 ce
lls
]
0
50
100
150
200
250
Vector control uPAR-del4/5 high uPAR-wt high
VN Co
l I
Co
l IV VN Co
l I
Co
l IV VN Co
l I
Co
l IV
*
* *
* *
*
 Figure 3   Adhesion of uPAR-del4/5 or uPAR-wt-overexpressing 
MDA-MB-231 cell clones to extracellular matrix proteins. 
 Ninety-six-well plates were coated with either VN (2  μ g/ml; BD 
Biosciences), Col I or Col IV (5  μ g/ml; Sigma-Aldrich), and cell 
adhesion was quantified as described in Figure 1B. At least three 
independent experiments were performed in triplicates each. The 
results are given in % relative to the cell number of adherent vector-
transfected control cells (mean  ±  SEM). Statistically significant 
differences ( p  <  0.05) to the vector control cells are indicated by an 
asterisk. 
(Sato et al., 2011). This effect, however, was much stronger 
pronounced in uPAR-del4/5 high-expressing cell clones 
(Figure 2B). The invasive capacity of cells with low expres-
sion of uPAR-del4/5 was not significantly different from 
that of vector control cells (Figure 2B). It is of note that 
breast cancer cells overexpressing uPAR-wt are character-
ized by a strong increase in its invasive capacity [data not 
shown; see also Sato et al. (2011)]. The observed effects on 
 in vitro invasion appear to be dependent on the level of 
uPAR-del4/5 protein, as the number of invaded cells, over-
expressing high levels of uPAR-del4/5, was significantly 
lower compared to the number of invaded cells in the low-
expressing cell clones (Figure 2B). 
 As processes such as tumor cell adhesion and inva-
sion depend on the expression and activity of adhesion 
molecules or matrix-degrading proteolytic enzymes, we 
investigated whether overexpression of uPAR-del4/5 in 
breast cancer cells modulates the expression of related 
tumor biologically relevant proteins. For this, gene expres-
sion of a series of tumor-associated proteases, inhibitors, 
and extracellular matrix proteins was analyzed in stably 
transfected vector control vs. uPAR-del4/5 high-expressing 
MDA-MB-231 breast cancer cells using a low-density micro-
array (Hauser et al. , 2011 ). Nine genes were found to be 
upregulated, and 11 genes downregulated more than ten-
fold in uPAR-del4/5 high-expressing cell clones compared 
to vector control cells (Table  1 ). mRNA expression levels of 
genes encoding the members of the plasminogen activa-
tion system (uPA, uPAR-wt, and PAI-1) were not affected. 
 Expression of one of the upregulated genes encoding 
the matrix metalloproteinase MMP-9 was further analyzed 
at the protein level (Ries et al. , 2007 ). For this, MMP-9 pro-
duction and secretion into the cell culture supernatant of 
uPAR-del4/5 and uPAR-wt high-expressing MDA-MB-231 
clones as well as vector control cells was determined in 
gelatin zymogram gels indicating a distinctly increased 
MMP-9 level in the cell culture supernatant of the uPAR-
del4/5 high-expressing clone (Figure  4 A). Western blot 
analysis, using a monoclonal antibody, IE-5E9-B1, directed 
to pro-MMP-9, in fact, confirmed enhanced secretion of 
MMP-9 into the supernatant of cultured breast cancer cells 
overexpressing uPAR-del4/5, but not uPAR-wt or vector 
control cells (Figure 4B). 
 In the present study, we found that the urokinase recep-
tor splice variant uPAR-del4/5 modulates unique tumor 
biological characteristics of breast cancer cells, depend-
ing on its protein expression level. Whereas, on one hand, 
overexpression of uPAR-del4/5 in MDA-MB-231 and CAMA-1 
cells did not have striking effects on cell growth, on the 
other, adhesive properties as well as the invasive capacity 
of cells were significantly impaired in a dose-dependent 
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manner in both breast cancer cell lines. Even very low 
uPAR-del4/5 protein levels clearly affected adhesion and 
invasion of breast cancer cells, which strongly indicates 
that uPAR-del4/5 expression leads to a pathophysiological 
modulation of cellular processes. Notably, overexpression 
of wild-type uPAR in MDA-MB-231 cells displays converse 
effects, i.e., increased cellular adhesion and invasion. 
 In clinical studies, quantification of uPAR-del4/5 
mRNA levels in breast cancer tissue revealed that higher 
uPAR-del4/5 expression is significantly associated with 
a shorter disease-free survival of breast cancer patients 
(Luther et al. , 2003 ; Kotzsch et al. , 2005, 2008 ). uPAR 
expression has been shown to be regulated by the RNA-
binding protein HuR  in vitro and  in vivo (Tran et al. , 2003 ; 
Heinonen et al. , 2011 ). Thus, the observed higher uPAR-
del4/5 mRNA expression in metastasizing breast cancer 
may be due to higher HuR expression in these tumors. 
Although high expression levels of both HuR and uPAR-
del4/5 in tumor tissue are clearly associated with poor 
prognosis of breast cancer patients, respectively,  in vitro 
overexpression of uPAR-del4/5, surprisingly, resulted in a 
reduced tumorigenic potential of transfected tumor cells. 
The observed phenotype of uPAR-del4/5-overexpressing 
cells resembles the phenotype of uPAR-wt-silenced cells, 
which are known to have a reduced invasive capacity  in 
vitro and  in vivo (Subramanian et al. , 2006 ; Kunigal et al. , 
2007 ). As uPAR-del4/5 protein does not interact with uPA 
and vitronectin (Sato et al. , 2010 ), it is tempting to specu-
late that uPAR-del4/5 acts as a dominant-negative recep-
tor by replacing/competing with endogenous uPAR-wt, 
which may lead to altered cell adhesion properties and 
cell signaling events. 
 Overexpression of uPAR-del4/5 in MDA-MB-231 breast 
cancer cells resulted in upregulation of tumor-related 
proteins, including MMP-9. MMPs are indeed upregulated 
in virtually all human and animal tumors as well as in 
most tumor cell lines [reviewed in Coussens et al.  (2002) ]. 
Similar to the plasminogen activator system, members of 
the MMP family have been implicated in tumor cell inva-
sion and metastasis by ECM degradation (Schmalfeldt 
et al. , 2001 ; Kessenbrock et al. , 2010 ). Moreover, MMPs 
promote initiation and sustained growth of tumor cells 
(Overall and L ó pez-Ot í n, 2002 ; Bauvois , 2011 ). Most 
uPAR-del4/5 overexpressing vs. vector control cells
Upregulation, more than 
10-fold
Downregulation, more than 
10-fold
MIP-1 β EMMPRIN
Cadherin-1 MIP-1 alpha
VEGFR Cyclin D2
HGF GCSF
Hepsin FAP
IL-1RA aFGF
Integrin α 4 IL-6R
MMP-9 MMP-13
Vitronectin MMP-3
Selectin
VCAM-1
 Table 1   Impact of uPAR-del4/5 overexpression on gene expression 
of tumor-associated genes. 
 mRNA was extracted from uPAR-del4/5 over-expressing or vector 
control cells and subjected to quantitative PCR-based low-density 
array analyses. mRNA isolation from cell lines and reverse transcrip-
tion to cDNA were done as described (Hauser et al. , 2011 ). All quan-
titative real-time PCRs on the array were performed with inventoried 
primers and probes from Applied Biosystem (Darmstadt, Germany). 
Data were normalized to human 18S rRNA (4319413E, RefSeq: 
X03205.1). Only genes that were either more than 10-fold upregu-
lated or repressed are listed. 
Vector
control
A
B
uPAR-
del4/5 high
uPAR-wt
high
HT1080 [kDa]
95
MMP-9
 Figure 4   MMP-9 expression in uPAR-del4/5-overexpressing MDA-MB-231 cells. 
 MDA-MB-231 cells transfected with the empty vector (pRcRSV), pRcRSV-uPAR-wt, or pRcRSV-uPAR-del4/5 were seeded onto untreated 
plates. Conditioned serum-free medium was collected after 48 h of incubation. (A) Zymographic analysis and quantification of gelatinases 
in zymograms. Zymography was performed in 10 % polyacrylamide minigels containing 0.1 % gelatin as substrate (Invitrogen). Samples 
were run under nonreducing conditions without prior boiling. Conditioned medium from PMA-treated HT1080 fibrosarcoma cells containing 
pro-MMP-9 (95 kDa) was used as marker. After electrophoresis, gels were washed twice for 15 min in renaturing buffer (Invitrogen) and then 
incubated in developing buffer (Invitrogen) for 72 h at 37 ° C. The zymograms were stained for 90 min with 0.02 % Coomassie Brilliant Blue 
R250 (Carl Roth, Karlsruhe, Germany) in a 30 % (v/v) methanol/10 % (v/v) acetic acid solution. (B) Western blot analysis. Immunoblotting 
was performed as described in Figure 1A, using the mouse monoclonal antibody IE-5E9-B1 directed to pro-MMP-9 as primary antibody. 
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MMPs are not expressed under normal quiescent condi-
tions, but their transcription can be induced in tumor 
or stromal cells by various signals, such as cytokines, 
growth factors, and oncogene products released by 
tumor cells themselves, by the stroma or infiltrating host 
defense cells [reviewed in Overall and L ó pez-Ot í n (2002) ]. 
Interestingly, uPAR-mediated signaling events trigger 
expression of MMP-9 during macrophage differentiation 
(Rao et al. , 1995 ). MMP-9 expression in tumor cells plays 
a crucial role in cell signaling by controlling the bioavail-
ability and bioactivity of molecules that target recep-
tors, which regulate cell growth and migration. Thus, 
concerning the elevated pro-MMP-9 levels monitored in 
conditioned medium of MDA-MB-231 cells overexpressing 
uPAR-del4/5, one would expect an enhanced proteolytic 
activity and, subsequently, a more invasive phenotype 
of these cells. Surprisingly, the opposite effect, impaired 
adhesive properties as well as decreased invasive capa-
city of these cells was observed. This phenomenon might 
be explained by either alterations in the activation of 
pro-MMP-9, an overexpression of MMP-9 inhibitors, 
or by additional nonproteolytic functions of MMP-9 in 
uPAR-del4/5-over-expressing breast cancer cells. In fact, 
there is growing evidence that MMPs under several cir-
cumstances do exhibit tumor-suppressing effects (Kes-
senbrock et al. , 2010 ; Bauvois , 2011 ; Klein and Bischoff , 
2011 ). All in all, our results point to a pathophysiologi-
cal role of uPAR-del4/5 expression in cancer cells among 
others  via modulation of gene expression of further 
tumor-associated factors such as MMP-9. 
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